BMS Features the P-III (CheckMate -9DW) Trial Data of Opdivo Plus Yervoy for Treating Advanced Hepatocellular Carcinoma at ASCO 2024
Shots:
- The P-III (CheckMate -9DW) study assesses Opdivo (1mg/kg, Q3W) + Yervoy (3mg/kg, Q3W) followed by Opdivo alone (480mg, Q4W) vs lenvatinib or sorafenib alone in advanced hepatocellular carcinoma patients (n=668) not treated with previous systemic therapy
- The study, at ~35.2mos. of median follow-up, demonstrated a 24% reduction in symptom deterioration risk, improved and consistent OS with mOS of 23.7mos. vs 20.6mos., ORR of 36% vs 13%, CR of 7% vs 2% and durable response with mDoR of 30.4mos. vs 12.9mos. among responders
- The safety profile aligned with the previous ones. Any grade TRAEs were reported in 84% vs 91% of patients and grade 3/4 TRAEs in 41% vs 42% of them
Ref: BMS | Image: BMS
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
